Home » ENDO ANNOUNCES COMMERCIAL AVAILABILITY OF OPANA ER (OXYMORPHONE HCL) EXTENDED-RELEASE AND OPANA (OXYMORPHONE HCL) IMMEDIATE-RELEASE TABLETS CII
ENDO ANNOUNCES COMMERCIAL AVAILABILITY OF OPANA ER (OXYMORPHONE HCL) EXTENDED-RELEASE AND OPANA (OXYMORPHONE HCL) IMMEDIATE-RELEASE TABLETS CII
Endo Pharmaceuticals Inc., a wholly owned subsidiary of Endo Pharmaceuticals Holdings Inc., has announced the commercial availability of Opana ER and Opana tablets. Endo has begun shipments
to its customers and is instituting a wholesale and retail stocking program to
ensure these products are distributed to retail pharmacies across the U.S. over
the next several weeks.
Drug
Newswire
KEYWORDS FDAnews Drug Daily Bulletin
Upcoming Events
-
07May
-
14May
-
30May